In the investigation conducted by Lale, A et al., clinicopathological aspects, namely HER-2 positivity, perineural invasion, SLN extranodal extension status, and a metastatic SLN diameter exceeding 10.5 mm, were found to be distinct risk factors for patients with breast cancer non-SLN metastasis. This evidence concerns the gene ERBB2 and breast cancer.